Abstract
Cell-targeting peptides which improve tissue-specific delivery of antisense oligonucleotides (AONs) are a new exciting “next-generation” potential AON therapy. New peptides are regularly developed which increase targeting and cell penetration for the AON treatment of mRNA misregulated diseases. Optimization of these peptide conjugate AONs requires systematic treatment and methods of analysis. This chapter describes methods for analyzing cell-targeting peptide conjugated AONs in primary cultured cell lines and for local and systemic delivery to the mouse for the treatment of Duchenne muscular dystrophy (DMD). Chimeric and novel cell-penetrating peptides have already been described to induce high levels of exon skipping and dystrophin protein expression in tissues body-wide at very low doses of AON. Screening of future novel peptides may be achieved by preliminary in vitro screening followed by in vivo administration of the most promising peptide-conjugated AONs. Physiological and functional correction of dystrophin protein may be confirmed by a number of techniques as described and allows for the fast-tracking of candidate peptides to drug trial for DMD.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abes R, Arzumanov A, Moulton H, Abes S, Ivanova G, Gait MJ et al (2008) Arginine-rich cell penetrating peptides: design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides. J Pept Sci 14:455–460
Wang Q, Yin H, Camelliti P, Betts C, Moulton H, Lee H et al (2010) In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. J Gene Med 12:354–364
Ivanova GD, Arzumanov A, Abes R, Yin H, Wood MJ, Lebleu B et al (2008) Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 36:6418–6428
Yin H, Moulton HM, Betts C, Seow Y, Boutilier J et al (2009) A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18:4405–4414
Wu B, Li Y, Morcos PA, Doran TJ, Lu P, Lu QL (2009) Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther 17:864–871
Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P et al (2008) Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17:3909–3918
Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S et al (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16:1624–1629
Wu B, Moulton HM, Iversen PL, Jiang J, Li J, Spurney CF et al (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 105:14814–14819
Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ et al (2009) In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11:257–266
Moulton HM, Wu B, Jearawiriyapaisarn N, Sazani P, Lu QL, Kole R (2009) Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy. Ann N Y Acad Sci 1175:55–60
Yin H, Lu Q, Wood M (2008) Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther 16:38–45
Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD et al (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12:175–177
Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102:198–203
Malerba A, Thorogood FC, Dickson G, Graham IR (2009) Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum Gene Ther 20:955–965
Ivanova GD, Fabani MM, Arzumanov AA, Abes R, Yin H, Lebleu B et al (2008) PNA-peptide conjugates as intracellular gene control agents. Nucleic Acids Symp Ser (Oxf) (52):31–32
Yin H, Saleh AF, Betts C, Camelliti P, Seow Y, Ashraf S et al (2011) Pip5 transductionpeptides direct high efficiency oligonucleotide-mediated dystrophin exonskipping in heart and phenotypic correction in mdxmice. Mol Ther 19(7):1295–1303
Seow Y, Yin H, Wood MJ (2010) Identification of a novel muscle targeting peptide in mdx mice. Peptides 31:1873–1877
Camelliti P, Gallagher JO, Kohl P, McCulloch AD (2006) Micropatterned cell cultures on elastic membranes as an in vitro model of myocardium. Nat Protoc 1:1379–1391
Acknowledgements
The authors would like to thank Professor Kay Davies (University of Oxford) for providing access to facilities including the mdx mouse colony, Mike Gait (MRC Laboratory of Molecular Biology, Cambridge) for close collaboration on novel peptide PMOs and for the provision of Pip peptide PMOs in particular, Hong Moulton (formerly of AVI Biopharma) for supplying the B-MSP-PMO AON, and Patrizia Camelliti for her assistance with the protocol for cardiomyocyte isolation. This work was supported by research grants awarded by Action Duchenne, the Muscular Dystrophy Campaign, Muscular Dystrophy Ireland, and Duchenne Ireland to MJAW.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Betts, C.A., Hammond, S.M., Yin, Hf., Wood, M.J.A. (2012). Optimizing Tissue-Specific Antisense Oligonucleotide–Peptide Conjugates. In: Aartsma-Rus, A. (eds) Exon Skipping. Methods in Molecular Biology, vol 867. Humana Press. https://doi.org/10.1007/978-1-61779-767-5_27
Download citation
DOI: https://doi.org/10.1007/978-1-61779-767-5_27
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-766-8
Online ISBN: 978-1-61779-767-5
eBook Packages: Springer Protocols